Aurobindo Pharma today reported 21.4 per cent rise in consolidated net profit at Rs 451.76 crore during the July-September quarter.
The pharma company had made a net profit of Rs 372.18 crore during the similar period of previous fiscal 2014-15.
"Total income is Rs 3,345.13 crore for the quarter ended September 30, 2015 whereas the same was at Rs 2,908.51 crore for the quarter ended September 30, 2014," it said in a BSE filing.
Also Read
Further, it said during the previous year, on December 4, 2014, the company's USA subsidiary Aurobindo Pharma USA Inc acquired Natrol LLC, USA.
"The consolidated results for the quarter and six months ended September 30, 2015 and for the year ended March 31, 2015 includes financial results of operations of Natrol LLC, USA from December 4, 2014," it said.
The corresponding figures of the quarter and six months ended September 30, 2014 are not comparable, it added.
The board of the company at its meeting today also considered and approved second interim dividend of 60 paise per equity share of Re 1 each on the equity share capital of the company for the year 2015-16.
The second interim dividend will be paid on or before November 27, 2015, it added.
The company, in September 2015, had paid first interim dividend of 50 per cent or 50 paise.
Further, it said that the board has revised approval for raising funds through issue of equity/GDRs/ADRs/FCCBs or any other equity related instruments upto an amount of USD 600 million or rupee equivalent after approval of the shareholders of the company and other necessary approvals.
Aurobindo Pharma shares closed at Rs 813.25 apiece on BSE, down 0.87 per cent from previous close.
